Calmark Sweden AB announced that the timetable for the clinical trial underway at Södersjukhuset has been updated. The first patient was included on 23 December, and the rate of inclusion has thus far been lower than expected. The study is now estimated to be finished within six weeks. As a consequence, the Company's first product, Neo-Bilirubin, will obtain its CE conformity marking during the first quarter instead of in January as previously disclosed. This will not impact the market launch. The clinical trial shall include 40 children, and is designed as a method-comparison study, where bilirubin analyzed with Calmark Neo is compared with the hospital laboratory's analytical results. The latter is used as the reference method in the comparison. The inclusion criterion is for the infant to have a suspected elevated level of bilirubin (risk of jaundice), requiring a blood test to be taken. The launch of the study coincided with the Christmas and New Year holiday period, and all units did not receive the information. As from this week, all units at Södersjukhuset are involved in the trial, and the infant inclusion rate is rising.